Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 2573

Researchers at Columbia University have developed a probiotic-guided chimeric antigen receptor (CAR)-T platform that uses engineered bacteria to infiltrate and produce synthetic antigen targets, enabling CAR-T cells to find, identify, and destroy tumor cells in situ. The results of in vivo preclinical tests suggest that the combined ProCAR cell therapy platform could expand the scope of CAR-T cell therapy to include difficult-to-target solid tumors.

Tal Danino, PhD, and Rosa L. Vincent, PhD, at Columbia University’s department of biomedical engineering, and colleagues, reported on their developments in Science, in a paper titled “Probiotic-guided CAR-T cells for solid tumor targeting,” in which they concluded, “These findings highlight the potential of the ProCAR platform to address the roadblock of identifying suitable CAR targets by providing an antigen that is orthogonal to both healthy tissue and tumor genetics … Overall, combining the advantages of tumor-homing bacteria and CAR-T cells provides a new strategy for tumor recognition and, in turn, builds the foundation for engineered communities of living therapies.”

Immunotherapies using CAR-T cells have proven successful in treating some types of blood cancers, but their efficacy against solid tumors remains elusive. A key challenge facing tumor-antigen targeting immunotherapies like CAR-T is the identification of suitable targets that are specifically and uniformly expressed on solid tumors, the authors noted. “A key challenge of antigen-targeted cell therapies relates to the expression patterns of the antigen itself, which makes the identification of optimal targets for solid tumor cell therapies an obstacle for the development of new CARs.” Solid tumors express heterogeneous and nonspecific antigens and are poorly infiltrated by T cells. As a result, the approach carries a high risk of fatal on-target, off-tumor toxicity, wherein CAR-T cells attack the targeted antigen on healthy vital tissues with potentially fatal effects.

Read more | >

In the realm of healthcare, change has always been met with resistance. It took considerable time for the medical community to accept the stethoscope as a valuable tool in patient care. Similarly, it will take a while for Artificial Intelligence (AI) to be recognized as a full-fledged health tool, despite its immense potential to revolutionize the healthcare industry. However, when A.I. eventually takes its rightful place in healthcare, it will displace the stethoscope as its symbol. Let’s dive into how AI is poised to transform the way we approach healthcare.

Read more | >

Inflammatory bowel disease (IBD) is a major global health concern, with an estimated 1.6 million cases in the US alone. While there are many treatments available, they are often ineffective and can cause harmful side effects. A major reason clinically successful IBD therapies remain elusive is because current model systems cannot replicate key mechanistic aspects of the epithelial inflammatory response in humans.

In this webinar brought to you by Altis Biosystems, Bryan McQueen will describe the development of a new stem-cell derived intestinal epithelium model system for testing IBD therapeutic efficacy. Using this model system, researchers developed a suite of assays to probe epithelial barrier disruption, cytotoxicity, and pro-inflammatory cytokine release in response to the activation of prototypical IBD-associated cellular pathways.

Read more | >

Ultracapacitors are awesome. But could they viably replace batteries in future electric vehicles?

Ultracapacitors have significant advantages over batteries, after all, they are much lighter, faster to charge, safer, and non-toxic. However, there are some areas where batteries wipe the floor with them, at least for now.

With recent acquisitions of ultracapacitor manufacturers by the likes of Tesla, ultracapacitors could be on the verge of ousting batteries as the go-to power source for electric cars.

Read more | >

In a move that echoes a sci-fi series, researchers have developed a super-small material that was able to not only stimulate nerves in rodents, but reconnect them as well. The finding could lead to injectable particles that take the place of larger implants.

In creating the particles, researchers at Rice University started with two layers of a metallic glass alloy called Metglas and wedged a piezoelectric layer of lead zirconium titanate in between them. Piezoelectric materials generate electricity when they have mechanical forces applied to them. Metglas is a magnetostrictive material, which means it changes its shape when it has a magnetic field applied to it. In this case, the change in shape of the Metglas in the presence of magnetic pulses caused the piezoelectric material inside to generate an electrical signal. Materials that do this are known as magnetoelectric.

“We asked, ‘Can we create a material that can be like dust or is so small that by placing just a sprinkle of it inside the body you’d be able to stimulate the brain or nervous system?’” said lead author Joshua Chen, a Rice doctoral alumnus. “With that question in mind, we thought that magnetoelectric materials were ideal candidates for use in neurostimulation. They respond to magnetic fields, which easily penetrate into the body, and convert them into electric fields – a language our nervous system already uses to relay information.”

Read more | >

The Higgs field is famous for its role bestowing mass on other particles. But it isn’t a one-way relationship: The Higgs field’s interactions also influence its own particle, the Higgs boson. Due to this give-and-take, some physicists think the Higgs boson should be approximately as heavy as the biggest mass scale with which it interacts, the Planck scale.

But this isn’t the case. The Planck scale sits at the enormous energies at which it is thought that gravity becomes as strong as the other three fundamental forces, around 1019 gigaelectronvolts. This is many orders of magnitude bigger than the actual Higgs mass of 125 GeV.

How can the gap between expectation and reality be so huge? Is something protecting the Higgs from Planck-scale physics? The large, unexpected difference in these two scales is known as the hierarchy problem.

Read more | >

Each October, the Nobel Prizes celebrate a handful of groundbreaking scientific achievements. And while many of the awarded discoveries revolutionize the field of science, some originate in unconventional places. For George de Hevesy, the 1943 Nobel Laureate in chemistry who discovered radioactive tracers, that place was a boarding house cafeteria in Manchester, U.K., in 1911.

De Hevesey had the sneaking suspicion that the staff of the boarding house cafeteria where he ate at every day was reusing leftovers from the dinner plates – each day’s soup seemed to contain all of the prior day’s ingredients. So he came up with a plan to test his theory.

Read more | >

In a suite of 21 papers published in the journals Science (12), Science Advances , and Science Translational Medicine , a large consortium of researchers shares new knowledge about the cells that make up our brains and the brains of other primates. It’s a huge leap from previously published work, with studies and data that reveal new insights about our nervous systems’ cellular makeup across many regions of the brain and what is distinctive about the human brain.

The research consortium is a concerted effort to understand the and its modular, functional nature. It was brought together by the National Institutes of Health’s Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative.

Hundreds of scientists from around the world worked together to complete a range of studies exploring the cellular makeup of the human and those of other primates, and to demonstrate how a transformative new suite of scalable techniques can be used to study the detailed organization of the human brain at unprecedented resolution.

Read more | >